You are here: Industry Insights > SPARC

News List

SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target expresspharma
December 06, 2021
Under the agreement, Biomodifying is eligible for an upfront payment, milestone payments on pre-specified clinical, regulatory, and commercial milestones, as well as royalties on sales.
SPARC declares positive results from Phase 3 clinical trial of PDP-716 to treat open-angle glaucoma or ocular hypertension expresspharma
May 14, 2021
Sun Pharma Advanced Research Company (SPARC) reported positive top-line results from its Phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension.
USFDA denies application from SPARC for cancer drug expresspharma
February 24, 2021
The Office of New Drugs of the US FDA requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis NDA.
SPARC announces Phase 3 trial results of SDN-037 to treat inflammation and pain of ocular surgery expresspharma
October 16, 2020
The primary efficacy measure was the proportion of subjects with an anterior chamber cell (ACC) grade of zero (0) on Day 15 (zero inflammation) which was met by a statistically significant number, reveal the positive top-line results.
SPARC signs license agreement with Tripoint Therapeutics for Elepsia XR tablets expresspharma
September 22, 2020
SPARC will be eligible to receive tiered royalties ranging from 15 per cent to 50 per cent on net sales.
SPARC and Sun Pharma enter into license agreement for SCD-044 expresspharma
May 29, 2020
Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries announced a worldwide licensing agreement on the development and commercialisation of SCD-044.
SPARC inks research collaboration pact with China’s HitGen expressbpd
March 14, 2019
Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments
HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration pharmafocusasia
March 13, 2019
HitGen Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) today announced a research collaboration to identify novel small molecule leads for targets of interest.
SPARC announces top-line results of Pivotal Bioequivalence Study expressbpd
November 26, 2018
Sun Pharma Advanced Research Company (SPARC) recently announced top-line results of the pivotal BE study for Paclitaxel Injection Concentrate for Suspension (PICS).
Sun Pharma, SPARC announce FDA approval of Xelpros financialexpress
September 17, 2018
Xelpros (latanoprost ophthalmic emulsion) 0.005 per cent for topical ophthalmic use is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost

Previous page 1 2 Next page